Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE1A | P54750 | 5/20 | 0.44 |
| ▸ | PDE1B | Q01064 | 5/20 | 0.44 |
| ▸ | PDE1C | Q14123 | 5/20 | 0.44 |
| ▸ | PDE2A | O00408 | 4/20 | 0.43 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.38 |
| ▸ | MEN1 | O00255 | 2/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.36 |
| ▸ | SLC16A1 | P53985 | 1/20 | 0.35 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.33 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.33 |
| ▸ | ADORA2B | P29275 | 1/20 | 0.33 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.33 |
| ▸ | USP1 | O94782 | 1/20 | 0.33 |
| ▸ | DCTPP1 | Q9H773 | 1/20 | 0.33 |
| ▸ | NR1D1 | P20393 | 1/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.33 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8513322 | 0.81 | PDE1B (0.46) | PDE1APDE1BPDE1CPDE2ACYP3A4 | |
| SCHEMBL2462419 | 0.81 | PDE1A (0.46) | PDE1APDE1BPDE1CPDE2ACYP3A4 | |
| SCHEMBL2455782 | 0.79 | PDE1B (0.42) | PDE1APDE1BPDE1CPDE2ACYP3A4 | |
| SCHEMBL2452774 | 0.77 | PDE1B (0.41) | PDE1APDE1BPDE1CPDE2ACYP3A4 | |
| SCHEMBL2458632 | 0.77 | SLC16A1 (0.57) | PDE1APDE1BPDE1CPDE2ACYP3A4 | |
| SCHEMBL2458000 | 0.75 | PDE1A (0.52) | PDE1APDE1BPDE1CPDE2ACYP3A4 | |
| SCHEMBL3389822 | 0.72 | PDE1B (0.43) | PDE1APDE1BPDE1CPDE2AMEN1 | |
| SCHEMBL12068584 | 0.71 | PDE1A (0.52) | PDE1APDE1BPDE1CPDE2AMEN1 | |
| SCHEMBL2462950 | 0.71 | PDE1B (0.50) | PDE1APDE1BPDE1CPDE2AMEN1 | |
| SCHEMBL2455867 | 0.71 | PDE1A (0.49) | PDE1APDE1BPDE1CPDE2AMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2367428-B1 | ORGANIC COMPOUNDS | INTRA CELLULAR THERAPIES INC (US) | 2016-04-06 | — | — | EP | disclosed |
| EP-2367428-B1 | ORGANIC COMPOUNDS | INTRA CELLULAR THERAPIES INC (US) | 2016-04-06 | — | — | EP | disclosed |
| US-20150353556-A1 | ORGANIC COMPOUNDS | LI PENG (US) | 2015-12-10 | — | — | US | disclosed |
| US-20150353556-A1 | ORGANIC COMPOUNDS | LI PENG (US) | 2015-12-10 | — | — | US | disclosed |
| US-20150353556-A1 | ORGANIC COMPOUNDS | LI PENG (US) | 2015-12-10 | — | — | US | disclosed |
| US-8927556-B2 | 1H-pyrrolo[3,4-D]pyrimidin-2(6H)-one compounds | INTRA-CELLULAR THERAPIES, INC. (US) | 2015-01-06 | — | — | US | disclosed |
| US-8927556-B2 | 1H-pyrrolo[3,4-D]pyrimidin-2(6H)-one compounds | INTRA-CELLULAR THERAPIES, INC. (US) | 2015-01-06 | — | — | US | disclosed |
| US-8927556-B2 | 1H-pyrrolo[3,4-D]pyrimidin-2(6H)-one compounds | INTRA-CELLULAR THERAPIES, INC. (US) | 2015-01-06 | — | — | US | disclosed |
| US-20120136013-A1 | ORGANIC COMPOUNDS | INTRA-CELLULAR THERAPIES. INC. | 2012-05-31 | — | — | US | disclosed |
| US-20120136013-A1 | ORGANIC COMPOUNDS | INTRA-CELLULAR THERAPIES. INC. | 2012-05-31 | — | — | US | disclosed |
| US-20120136013-A1 | ORGANIC COMPOUNDS | INTRA-CELLULAR THERAPIES. INC. | 2012-05-31 | — | — | US | disclosed |
| EP-2367428-A1 | ORGANIC COMPOUNDS | Intra-Cellular Therapies, Inc. (US) | 2011-09-28 | — | — | EP | disclosed |
| WO-2010065147-A1 | ORGANIC COMPOUNDS | INTRA-CELLULAR THERAPIES, INC. (US) | 2010-06-10 | — | — | WO | disclosed |
| WO-2010065147-A1 | ORGANIC COMPOUNDS | INTRA-CELLULAR THERAPIES, INC. (US) | 2010-06-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150353556-A1 | ORGANIC COMPOUNDS | CYP2C9, TPMT, CYP2C19 | PDE1A 4874/4885PDE1B 4863/4885PDE1C 4862/4885 |
| US-20120136013-A1 | ORGANIC COMPOUNDS | CYP2C9, CYP2C19, CYP3A4 | PDE1A 4874/4885PDE1B 4855/4885PDE1C 4854/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.